Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Shift from systemic to site-specific memory by tumor-targeted IL-2.

David Schrama1, Rong Xiang, Andreas O Eggert

  • 1Department of Dermatology, Julius-Maximilians University, Würzburg, Germany.

Journal of Immunology (Baltimore, Md. : 1950)
|May 7, 2004
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RB1 inactivation in cutaneous carcinomas.

Histopathology·2025
Same author

Sorafenib as first-line therapy for metastatic uveal melanoma: A multicenter, placebo-controlled randomized discontinuation study (STREAM).

iScience·2025
Same author

MEK5/ERK5 inhibition sensitizes NRAS-mutant melanoma to MAPK-targeted therapy by preventing Cyclin D/CDK4-mediated G1/S progression.

Cell death & disease·2025
Same author

Optimization of Adcitmer, a Monomethyl-Auristatin E bearing antibody-drug conjugate for the treatment of CD56-expressing cancers.

Journal for immunotherapy of cancer·2025
Same author

Short- and long-term immunosuppressive effects of melanoma influence the prognostic value of the sentinel lymph node status.

European journal of cancer (Oxford, England : 1990)·2024
Same author

Wnt/β-Catenin-Activated Nonpilomatrical Carcinoma of the Skin: A Case Series.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2024

Targeted interleukin-2 (IL-2) boosts local anti-cancer immunity but impairs systemic memory. This approach may hinder long-term protection against melanoma metastases, despite initial tumor rejection.

Area of Science:

  • Immunology
  • Oncology
  • Cancer Vaccines

Background:

  • Interleukin-2 (IL-2) is an approved cancer treatment and vaccine component.
  • IL-2 is crucial for effective immune responses against cancer, including melanoma.
  • Previous studies showed IL-2 is required for dendritic cell-based peptide vaccination against melanoma metastases.

Purpose of the Study:

  • To confirm the necessity of IL-2 in dendritic cell-based peptide vaccination against melanoma.
  • To investigate the effects of tumor-targeted IL-2 on immune response and memory development.
  • To analyze the impact of targeted IL-2 on tumor-reactive T cell distribution.

Main Methods:

  • Utilized tumor-targeted IL-2 in a mouse model of melanoma.
  • Administered dendritic cell-based peptide vaccination with tyrosinase-related protein 2 peptides.

Related Experiment Videos

  • Assessed tumor rejection, systemic memory, and T cell populations after vaccination and rechallenge.

    • Main Results:

    • Tumor-targeted IL-2 confirmed its requirement for effective anti-melanoma immune response.
    • Systemic memory development was significantly impaired, leading to failure in rejecting pulmonary metastases upon rechallenge.
    • Targeted IL-2 expanded local effector T cells but depleted tumor-reactive T cells from lymphatic tissues.

    Conclusions:

    • While tumor-targeted IL-2 enhances local anti-cancer immunity, it compromises protective systemic memory.
    • This strategy may limit long-term efficacy against metastatic cancer.
    • Further research is needed to optimize IL-2-based cancer therapies for durable immune memory.